

July 23, 2026

To,

General Manager, Listing Department, Bombay Stock Exchange Limited, P.J. Towers, Dalal Street, Mumbai – 400 001 Company code: 533333	The Manager, Listing & Compliance Department The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai - 400051 Company code: FCL
---	---

Subject: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to regulation 30, 33 and schedule III (Part A) of SEBI (Listing Obligations and Disclosures) Regulations, 2015, we wish to inform you that the meeting of the Board of Directors held on July 23, 2026, which commenced at **3.50 P.M.** and concluded at **5.00 P.M.** has inter-alia considered and approved;

1. The Unaudited Standalone and Consolidated financial results and the Limited Review Reports of the Statutory Auditors thereon for the quarter ended June 30, 2026;

We enclosed a copy of the Standalone and Consolidated Unaudited Financial Results along with the Limited Review Report of the Statutory Auditors thereon for the quarter ended June 30, 2026.

Page No. 1

Highlights of Consolidated Business**Consolidated Quarter Q1-FY 2026-2027 (Y-o-Y Basis)**

1. Total Income from Operation for the Quarter has **increased to Rs. 38,672 Lakhs** from **Rs. 14,622 Lakhs** i.e., a **growth of 164.48 %**.
2. Operational EBITDA for the quarter has **increased to ~Rs. 5,914 Lakhs** from **~Rs. 2,520 Lakhs** i.e., a **growth of ~ 134.74 %**.
3. Profit after tax (PAT) for the quarter ended has **increased to Rs. 4,821 Lakhs** from **Rs. 2,503 Lakhs** i.e., a **growth of 92.61 %**.

Other Highlights of Q1 for the Financial Year 2026-2027

1. The consolidated Return on Invested Capital (ROIC) for Q1-FY 2026-2027 is ~ **33.06 %**.
2. **Volume Growth:** The volume of the consolidated business for the Quarter ended has increased by ~ **130.84%** on Y-o-Y basis.

Kindly take the above information on your records and oblige.

Thanking you,

Yours faithfully,

For FINEOTEX CHEMICAL LIMITED

Sanjay Tibrewala

Executive Director and CFO

DIN: 00218525

Encl: As above



Page No. 2

Independent Auditor's Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors
Fineotex Chemical Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited financial results of Fineotex Chemical Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



Fineotex Chemical Limited
Independent Auditor's Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

4. The Statement includes the results of the following entities:

Name of Entities	Relationship
1. Manya Manufacturing India Private Limited (Formerly Known as Manya Steels Private Limited)	Wholly Owned Subsidiary
2. Fineotex Biotex Healthguard FZE (Formerly Known as Fineotex Specialities FZE)	Wholly Owned Subsidiary
3. Fineotex Malaysia Limited	Wholly Owned Subsidiary
4. FSPL Specialities Private Limited (Formerly Known as Fineotex Specialities Private Limited)	Wholly Owned Subsidiary
5. Finoclean Specialities Private Limited	Wholly Owned Subsidiary
Subsidiaries of Fineotex Malaysia Limited	
6. BT Chemicals SDN.BHD.	Subsidiary
7. BT Biotex SDN.BHD.	Subsidiary
8. Rovatex SDN. BHD.	Subsidiary
9. BT. Biotex Limited	Wholly Owned Subsidiary
Subsidiaries of Fineotex Biotex Healthguard FZE	
10. CrudeChem Technology LLC	Subsidiary
11. FrackMex Equipment and Services LLC	Subsidiary
12. Lonestar Technoboost LLC	Subsidiary
13. Oil Pro Advantage INC	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the unreviewed and unaudited interim financial information prepared and furnished to us by the management and approved by the Board of Directors of the Parent Company referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 specified under Section 133 of the Act, as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.



Fineotex Chemical Limited**Independent Auditor's Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

6. The consolidated unaudited financial results includes the interim financial information of Thirteen subsidiaries which have not been reviewed and are not audited, whose interim financial information reflects (before eliminating intercompany transactions) total revenue of ₹. 31,082.51 Lakhs and total profit after tax of ₹. 2,767.94 Lakhs for the quarter ended June 30, 2026, as considered in the consolidated unaudited financial results. These interim financial information are not reviewed and are unaudited and have been prepared and furnished to us by the management of the Parent Company and our opinion on the unaudited consolidated financial results, in so far as it relates to the amounts included in the consolidated unaudited financial results in respect of these subsidiary companies, is based solely on such unreviewed and unaudited interim financial information prepared and furnished to us by the management of the Parent Company and approved by the Board of Directors of the Parent Company.

Our Conclusion on the Statement is not modified in respect of our reliance on the unreviewed and unaudited interim financial information of these subsidiary companies certified by the Management of the Parent Company and approved by the Board of Directors of the Parent Company.

For ASL & Co.
Chartered Accountants
(Regn No. 101921W)

(Shikha Jain)
Partner
Membership No.: 136484
UDIN: 26136484NOJKOI2743



Place: Mumbai
Date: 23rd July, 2026.

FCL FINEOTEX CHEMICAL LIMITED

(Company Identification Number: L24100MH2004PLC144295)

Regd. Off.: Level 4, Ariisto House, Opp. Hubtown Solaris, Andheri (E), Mumbai-400069, India.

Tel: 022-26559174-77, Fax: 022-22659178, Email: info@fineotex.com, Web: www.fineotex.com

(₹ In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026				
PARTICULARS	Quarter ended			Year Ended
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited	Unaudited	Audited
1 Income				
(a) Revenue from operation	37,662.77	31,373.42	13,707.20	77,222.56
(b) Other Income	1,008.89	945.70	914.48	3,307.00
Total Income	38,671.66	32,319.12	14,621.68	80,529.56
2 Expenses				
(a) Cost of materials consumed	24,831.46	22,474.95	8,275.79	51,235.76
(b) Purchase of stock-in-trade	-	92.04	855.76	1,811.55
(c) Changes in inventories of finished goods, work-in-process and stock-in-trade	(508.68)	(314.57)	(20.08)	(1,311.09)
(d) Employee benefits expenses	2,683.20	1,737.39	619.99	4,035.45
(e) Finance costs	10.10	62.79	15.67	136.19
(f) Depreciation and amortization expenses	438.88	439.67	268.97	1,342.47
(g) Other expenses	4,742.43	3,014.73	1,456.18	7,975.96
Total expenses	32,197.39	27,506.99	11,472.28	65,226.29
3 Profit before tax (1-2)	6,474.27	4,812.13	3,149.40	15,303.27
4 Tax expenses				
(a) Current Tax	1,689.98	538.17	502.06	2,653.84
(b) Deferred Tax	(36.24)	(105.52)	144.50	147.92
5 Profit after tax (3-4)	4,820.53	4,379.48	2,502.84	12,501.51
Attributable to:				
(a) Owners of the Company	3,839.77	3,160.84	2,481.09	10,875.22
(b) Non-Controlling Interest	980.77	1,218.64	21.75	1,626.29
6 Other Comprehensive Income (OCI) (net of tax)	5.75	17.31	(3.86)	23.01
7 Total Comprehensive Income for the period (5+6)	4,826.29	4,396.79	2,498.98	12,524.52
Attributable to:				
(a) Owners of the Company	3,845.52	3,178.15	2,477.23	10,898.23
(b) Non-Controlling Interest	980.77	1,218.64	21.75	1,626.29
8 Paid-up Equity share capital (Face Value ₹ 1/- each)	11,645.01	11,645.01	2,291.50	11,645.01
9 Other Equity (Excluding Revaluation Reserve if any)				76,598.13
10 Earnings per Share (of ₹ 1/- each) (for Quarter ended not annualised):				
a) Basic & Diluted (₹/share)	0.41	0.38	1.09	1.09



Notes:

- 1 The above consolidated results were reviewed and recommended by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 23rd July, 2026. The above results have been subjected to Limited Review by the Statutory Auditors of the Company. The Statutory Auditors have expressed an unqualified report on the above results.
- 2 This Statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 3 These financial results together with the results of previous period have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The figures of preceding quarter (i.e., three months ended March 31, 2026) are the balancing figures between the audited figure in respect of the full financial year and the published year to date figures upto the end of third quarter of the preceding financial year, which have been subject to limited review.
- 5 The Board of directors of the Company at their meeting held on Friday, 15th May, 2026 recommended a final dividend of ₹ 0.05/- per equity share of face value of ₹ 1/- each, for the financial year ended 31st March, 2026. Final Dividend is Subject to approval of Shareholders.
- 6 The Company mainly operates in a single primary business segment of Speciality Chemicals, therefore disclosure requirements as per Ind AS 108, "Operating Segments" are not applicable to the Company.
- 7 Previous periods figure have been regrouped, rearranged, reclassified wherever necessary to correspond with those of the current period.
- 8 The Notes on the above results were approved at the meeting of the Board of Directors of the Company held on 23rd July, 2026.
- 9 The legal dispute concerning the Assignment Agreement for the property under 'Assets Held for Sale' had not been settled as of June 30, 2026

As of June 30, 2026, the company has paid Rs. 625.00 lakhs towards the settlement of the dispute.

During Quarter 4 of the previous year, the company entered into a Memorandum of Understanding (MOU) with a third party for the transfer/assignment of the aforementioned Property Held for Sale. As of June 30, 2026, the company has received a total advance of Rs.1,008.00 lakhs (Rs.800.00 lakhs in Q4 of the previous year and Rs.208.00 lakhs in the current quarter)

As the transfer of the property had not been completed by 30 June 2026, the sale has not been recognised.



Place: Mumbai
Date: 23rd July, 2026

For and on behalf of the Board of Directors

Surendrakumar Tibrewala
Chairman & Managing Director
DIN 00218394

Sanjay Tibrewala
CFO & Executive Director
DIN 00218525

Independent Auditor's Review Report on the Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**Review Report to
The Board of Directors
Fineotex Chemical Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone financial results (the "Statement") of Fineotex Chemical Limited (the "Company") for the quarter ended June 30, 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"),
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 ("the Act") as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Fineotex Chemical Limited**Independent Auditor's Review Report on the Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 specified under Section 133 of the Act, as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ASL & Co.
Chartered Accountants
(Regn No. 101921W)

(Shikha Jain)
Partner
Membership No.: 136484
UDIN: 26136484LXBJJB2318



Place: Mumbai
Date: 23rd July, 2026.

FCL FINEOTEX CHEMICAL LIMITED

(Company Identification Number: L24100MH2004PLC144295)

Regd. Off.: Level 4, Ariisto House, Opp. Hubtown Solaris, Andheri (E), Mumbai-400069, India.

Tel: 022-26559174-77, Fax: 022-22659178, Email: info@fineotex.com, Web: www.fineotex.com

(₹ In lakhs)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026				
PARTICULARS	Quarter ended			Year Ended
	30-06-2026	31-03-2026	30-06-2025	31-03-2026
	Unaudited	Audited	Unaudited	Audited
1 Income				
(a) Revenue from operation	8,514.55	9,759.98	9,825.59	39,687.83
(b) Other Income	1,078.10	741.29	996.71	4,108.88
Total Income	9,592.65	10,501.27	10,822.30	43,796.71
2 Expenses				
(a) Cost of materials consumed	5,278.39	5,966.58	6,531.07	25,388.08
(b) Purchase of stock-in-trade	-	-	-	-
(c) Changes in inventories of finished goods, work-in-process and stock-in-trade	(251.09)	(14.89)	54.92	(669.58)
(d) Employee benefits expenses	681.56	696.76	538.56	2,401.64
(e) Finance costs	19.26	17.14	10.62	52.95
(f) Depreciation and amortization expenses	218.19	213.40	200.81	838.52
(g) Other expenses	1,236.14	1,186.11	1,001.57	4,440.12
Total expenses	7,182.45	8,065.09	8,337.55	32,451.73
3 Profit before tax (1-2)	2,410.20	2,436.18	2,484.75	11,344.99
4 Tax expenses				
(a) Current Tax	415.00	433.16	376.07	2,059.23
(b) Deferred Tax	(57.40)	(110.48)	119.30	96.80
5 Profit after tax (3-4)	2,052.60	2,113.50	1,989.38	9,188.96
6 Other Comprehensive Income (OCI) (net of tax)	5.75	17.31	(3.86)	23.01
7 Total Comprehensive Income for the period (5+6)	2,058.35	2,130.81	1,985.52	9,211.97
8 Paid-up Equity share capital (Face Value ₹ 1/- each)	11,645.01	11,645.01	2,291.50	11,645.01
9 Other Equity (Excluding Revaluation Reserve if any)				63,773.89
10 Earnings per Share (of ₹ 1/- each) (for Quarter ended not annualised):				
a. Basic & Diluted (₹/share)	0.18	0.18	0.87	0.80



Notes:

- 1 The above results were reviewed and recommended by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 23rd July, 2026. The above results have been subjected to Limited Review by the Statutory Auditors of the Company. The Statutory Auditors have expressed an unqualified report on the above results.
- 2 This Statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
- 3 These financial results together with the results of previous period have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 4 The figures of preceding quarter (i.e., three months ended March 31, 2026) are the balancing figures between the audited figure in respect of the full financial year and the published year to date figures upto the end of third quarter of the preceding financial year, which have been subject to limited review.
- 5 The Board of directors of the Company at their meeting held on Friday, 15th May, 2026 recommended a final dividend of ₹ 0.05/- per equity share of face value of ₹ 1/- each, for the financial year ended 31st March, 2026. Final Dividend is Subject to approval of Shareholders.
- 6 The Company mainly operates in a single primary business segment of Speciality Chemicals, therefore disclosure requirements as per Ind AS 108, "Operating Segments" are not applicable to the Company.
- 7 Previous periods figure have been regrouped, rearranged, reclassified wherever necessary to correspond with those of the current period.
- 8 The Notes on the above results were approved at the meeting of the Board of Directors of the Company held on 23rd July, 2026.
- 9 The legal dispute concerning the Assignment Agreement for the property under 'Assets Held for Sale' had not been settled as of June 30, 2026.
As of June 30, 2026, the company has paid Rs. 625.00 lakhs towards the settlement of the dispute.
During Quarter 4 of the previous year, the company entered into a Memorandum of Understanding (MOU) with a third party for the transfer/assignment of the aforementioned Property Held for Sale. As of June 30, 2026, the company has received a total advance of Rs.1,008.00 lakhs (Rs.800.00 lakhs in Q4 of the previous year and Rs.208.00 lakhs in the current quarter)
As the transfer of the property had not been completed by 30 June 2026, the sale has not been recognised.

Place: Mumbai
Date: 23rd July, 2026



For and on behalf of the Board of Directors

S. Tibrewala

Surendrakumar Tibrewala
Chairman & Managing Director
DIN 00218394

S. Tibrewala

Sanjay Tibrewala
CFO & Executive Director
DIN 00218525